Barinthus Biotherapeutics plc (BRNS) Stock Score, Valuation & Financial Research

Barinthus Biotherapeutics plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BRNS

Barinthus Biotherapeutics plc does not currently have a complete Wall Street Score. The stored market price is USD 0.74. These figures are a research snapshot, not a buy or sell recommendation.

What Barinthus Biotherapeutics plc does

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its proprietary immunotherapeutic drug candidates.

Products and services

  • The company develops antigen-specific immunotherapeutic candidates, including VTP-1000 for celiac disease and VTP-300 for chronic hepatitis B, designed to modulate the immune system to treat autoimmune and inflammatory diseases.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary Vaxinia and ChAdOx1 technology platforms Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical research organizations Source
  • Uncertainty regarding clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BRNS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.74
Market capitalization:
30.23M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -41.74M
Free cash flow:
USD -48.02M
Cash:
USD 59.3M
Total debt:
USD 10.3M
EPS:
USD -1.03

What stands out

  • Free cash flow is USD -48.02M, negative for the stored period.
  • The balance sheet shows USD 59.3M of cash versus USD 10.3M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 49M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BRNS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BRNS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BRNS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BRNS to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BRNS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BRNS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.